|
See related Votrient film-coated tab information |
|
|
|
Manufacturer |
GlaxoSmithKline |
|
Distributor |
Hong Kong: Zuellig/Macau: Firma Chun Cheong |
|
Contents |
Pazopanib HCl |
|
Indications |
1st-line treatment of advanced renal cell carcinoma & for patients who received prior cytokine therapy for advanced disease.
Click to view Votrient detailed prescribing infomation |
|
Dosage |
Adult 800 mg once daily.
Click to view Votrient detailed prescribing infomation |
|
Overdosage |
View Votrient overdosage for action to be taken in the event of an overdose. |
|
Administration |
Should be taken on an empty stomach (Take at least 1 hr before or 2 hr after meals. Swallow whole, do not chew/crush. Do not eat/drink grapefruit products.). |
|
Contraindications |
Severe hepatic impairment. Hypersensitivity to pazopanib or to any of the excipients.
Click to view Votrient detailed prescribing infomation |
|
Special Precautions |
Mild or moderate hepatic impairment. Close monitoring of serum liver tests. HTN, QT interval prolongation, MI, ischemic stroke, transient ischaemic attack. Haemorrhage. GI perforation or fistula. Periodic monitoring of thyroid function. Baseline & periodic monitoring of ECG & electrolytes; urinalysis. Pregnancy & in women of childbearing potential not using contraception. Lactation. Elderly ≥65 yr. Childn & adolescents <18 yr.
Click to view Votrient detailed prescribing infomation |
|
Adverse Drug Reactions |
Decreased appetite, dysguesia, HTN, GI disturbances, fatigue, increased ALT & AST, hair colour change.
View ADR Monitoring Form |
|
Drug Interactions |
Ketoconazole, itraconazole, voriconazole, clarithromycin, telithromycin, atazanavir, indinavir, nefazodone, nelfinavir, ritonavir, saquinavir, lapatinib, rifampin, caffeine, warfarin, omeprazole, midazolam, dextromethorphan, paclitaxel, rosuvastatin. Grapefruit juice, high-fat or low-fat meal.
View more drug interactions with Votrient |
|
Pregnancy Category (US FDA) |
Category D: There is positive evidence of human foetal risk, but the benefits from use in pregnant women may be acceptable despite the risk (e.g., if the drug is needed in a life-threatening situation or for a serious disease for which safer drugs cannot be used or are ineffective). |
|
Description |
View Votrient description for details of the chemical structure and excipients (inactive components). |
|
Mechanism of Action |
View Votrient mechanism of action for pharmacodynamics and pharmacokinetics details. |
|
ATC Classification |
L01XE11 - pazopanib ; |
|
Presentation/Packing |
|
Form |
Packing |
Photo |
|
Votrient film-coated tablet |
|
|
|
Manufacturer: |
GlaxoSmithKline |
|
Distributor: |
Hong Kong: Zuellig
Macau: Firma Chun Cheong |
|
 |
|
|
|
